Takeda/Millennium’s Phase III IBD Drug Promises Improved Safety
This article was originally published in PharmAsia News
Executive Summary
Millennium Pharmaceuticals, which in this case could call itself "The Takeda Gastroenterology Company," announced Jan. 22 that it has launched Phase III trials of its anti-inflammatory biologic MLN0002 in two kinds of inflammatory bowel disease